Tesamorelin for Weight Loss & Fat Reduction — Clinical Evidence & Future Directions
A research summary covering Tesamorelin’s relevance in visceral fat reduction, metabolic improvement, hepatic fat research, and broader body-composition studies.
Why Visceral Fat Research Matters
Central adiposity and visceral adipose tissue are important research areas because they are closely linked with metabolic syndrome, cardiovascular risk, insulin resistance, and inflammatory markers. Tesamorelin has been studied for its selective effect on visceral fat depots.
Mechanism of Action
Tesamorelin stimulates growth hormone release, which increases IGF-1 levels. In research contexts, this pathway is associated with lipolysis, particularly in visceral fat tissue, while preserving broader physiological feedback mechanisms.
Research Findings
- VAT reduction: Studies reported 15–20% VAT reduction in HIV-positive populations over approximately 6 months.
- Non-HIV research: Broader populations have been studied with reported VAT reduction outcomes over 26 weeks.
- Triglyceride markers: Research discussed significant reductions in fasting triglycerides.
- Hepatic fat research: Tesamorelin has also been studied in relation to liver fat content and NAFLD-related models.
Comparison with Other Research Pathways
Compared with direct growth hormone administration, Tesamorelin is studied for supporting pulsatile GH release and targeting visceral adiposity while reducing concerns connected to sustained GH elevation.
Explore Tesamorelin Fat Reduction Research
View research-grade Tesamorelin and read the complete guide for wider mechanism and application context.